Newly appointed ScinoPharm Taiwan Ltd (台灣神隆) president Tony Su (蘇崇銘) yesterday said that he would oversee the company’s transition amid immense changes in global markets and supply chains.
“My first responsibility at the company would be to oversee continuation of organizational restructuring and cost management,” Su told an earnings conference.
He said that the global market for generic drugs has been reshuffled by rapid consolidation and the company faces increasing challenges as prices trend lower.
Apart from changing its chief financial and research and development officers, there has not been a major shift in the management team, although key executives would take on additional roles to better align them with the company’s objectives, Su said.
Su was previously with Uni-President Enterprises Corp (UPE, 統一企業), a major investor in ScinoPharm.
ScinoPharm, which makes active pharmaceutical ingredients (APIs), as well as providing contract manufacturing and research services, said that it would begin to see profit contribution from a newly approved generic oncology injection that was developed with US-based Sagent Pharmaceutical Inc.
ScinoPharm said that its generic version of anti-thrombotic drug Fondaparinux in March gained approval from the US Food and Drug Administration and is to begin sales in the US in two to three months time.
The anti-thrombotic drug is also expected to gain market approval from Indian authorities and commence sales there this year, the company said.
This year, ScinoPharm has gained regulatory approval in China to supply generic APIs for a treatment for benign prostatic hyperplasia and a generic oncology injectible for myeloid leukemia in the US.
The company has observed a significant shift in China’s API supply chain as Beijing tightens environmental requirements, ScinoPharm marketing and sales vice president Portia Lin (林靜雯) said.
China has been ordering noncompliant manufacturers to shut down, leading to disruptions in the supply and pricing of chemicals, Lin said.
The company has minimized the disruption by importing from other markets, Lin said, adding that China’s new plant inspection regimen and stricter drug license approvals should help push out low-quality API suppliers.
The company reported that net income in the second quarter dipped 3 percent quarterly to NT$131 million (US$4.27 million), although revenue rose 14 percent to NT$986 million on the back of strong sales of colorectal cancer products. Earnings per share (EPS) were NT$0.17.
In the April-to-June period, gross margin and operating margin were 43 percent and 16 percent respectively, up from 39 percent and 14 percent in the previous period.
Overall, net income in the first half rose 5 percent annually to NT$267 million, or EPS of NT$0.34, while sales gained 4 percent to reach NT$1.85 billion.
IN THE AIR: While most companies said they were committed to North American operations, some added that production and costs would depend on the outcome of a US trade probe Leading local contract electronics makers Wistron Corp (緯創), Quanta Computer Inc (廣達), Inventec Corp (英業達) and Compal Electronics Inc (仁寶) are to maintain their North American expansion plans, despite Washington’s 20 percent tariff on Taiwanese goods. Wistron said it has long maintained a presence in the US, while distributing production across Taiwan, North America, Southeast Asia and Europe. The company is in talks with customers to align capacity with their site preferences, a company official told the Taipei Times by telephone on Friday. The company is still in talks with clients over who would bear the tariff costs, with the outcome pending further
NEGOTIATIONS: Semiconductors play an outsized role in Taiwan’s industrial and economic development and are a major driver of the Taiwan-US trade imbalance With US President Donald Trump threatening to impose tariffs on semiconductors, Taiwan is expected to face a significant challenge, as information and communications technology (ICT) products account for more than 70 percent of its exports to the US, Chung-Hua Institution for Economic Research (CIER, 中華經濟研究院) president Lien Hsien-ming (連賢明) said on Friday. Compared with other countries, semiconductors play a disproportionately large role in Taiwan’s industrial and economic development, Lien said. As the sixth-largest contributor to the US trade deficit, Taiwan recorded a US$73.9 billion trade surplus with the US last year — up from US$47.8 billion in 2023 — driven by strong
AI: Softbank’s stake increases in Nvidia and TSMC reflect Masayoshi Son’s effort to gain a foothold in key nodes of the AI value chain, from chip design to data infrastructure Softbank Group Corp is building up stakes in Nvidia Corp and Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), the latest reflection of founder Masayoshi Son’s focus on the tools and hardware underpinning artificial intelligence (AI). The Japanese technology investor raised its stake in Nvidia to about US$3 billion by the end of March, up from US$1 billion in the prior quarter, regulatory filings showed. It bought about US$330 million worth of TSMC shares and US$170 million in Oracle Corp, they showed. Softbank’s signature Vision Fund has also monetized almost US$2 billion of public and private assets in the first half of this year,
POWELL SUCCESSOR: US Fed Governor Adriana Kugler’s resignation gives Donald Trump an opening on the board, potentially accelerating his decision on the next chair US President Donald Trump suddenly has a chance to fill an opening at the US Federal Reserve earlier than expected, after Fed Governor Adriana Kugler announced her resignation on Friday. It might also force him to pick the next Fed chair months sooner than he had anticipated. “The ball is now in Trump’s court,” LH Meyer/Monetary Policy Analytics Inc economist Derek Tang said. “Trump is the one who’s been putting pressure on the Fed to do this and that, and Trump says he wants to have his own people on. So now he has the opportunity.” Kugler’s exit unfolds amid unprecedented public pressure
RSS